**Core Concept**
Pseudocholinesterase deficiency is a genetic disorder characterized by a deficiency of the enzyme butyrylcholinesterase, which is responsible for the breakdown of certain muscle relaxants and other ester-based compounds. This deficiency can lead to prolonged apnea and muscle weakness due to the accumulation of these substances.

**Why the Correct Answer is Right**
The correct answer is a drug that relies on pseudocholinesterase for its metabolism. Succinylcholine is a depolarizing muscle relaxant that is metabolized by pseudocholinesterase, and a deficiency of this enzyme can lead to prolonged apnea and muscle weakness. This is because the drug is not broken down quickly enough, allowing it to continue to act on the muscle receptors.

**Why Each Wrong Option is Incorrect**
**Option A:** Vecuronium is a non-depolarizing muscle relaxant that is not metabolized by pseudocholinesterase, making it a safer choice in patients with this deficiency.
**Option B:** Pancuronium is also a non-depolarizing muscle relaxant and is not affected by pseudocholinesterase levels.
**Option C:** Fentanyl is an opioid analgesic that is not metabolized by pseudocholinesterase and is not contraindicated in patients with this deficiency.

**Clinical Pearl / High-Yield Fact**
In patients with pseudocholinesterase deficiency, it is essential to use non-depolarizing muscle relaxants or those that are not metabolized by the enzyme, such as vecuronium or rocuronium. Additionally, the use of succinylcholine should be avoided or used with caution, and the patient's apnea should be closely monitored.

**Correct Answer: C. Fentanyl.**